Roche won the U.S. Food and Drug Administration’s breakthrough therapy tag for Gazyva in lupus nephritis, boosting the Swiss drugmaker’s efforts to recycle the 2013-approved lymphoma medicine for new indications.
Top 200 Medicines Annual Report 2019: The king of medicines
Ankylosing Spondylitits, August 2019, Autoimmune Diseases, Biologics, Biosimilars, Blockbusters, Cervical Cancer, Classical Hodgkin Lymphoma, Crohn's Disease, Esophageal Cancer, Forecasts, Gastric Cancer, Head & Neck Cancer, Hepatocellular Carcinoma, Hidradenitis suppurativa, Issue Archives, Juvenile Idiopathic Arthritis, Market exclusivity, Melanoma, Merkel cell carcinoma, Metastatic Urothelial Carcinoma (mUC), Microsatellite instability-high (MSI-H) cancer, Monoclonal Antibodies, Non-Small Cell Lung Cancer (NSCLC), Plaque Psoriasis, Primary lediastinal large B-cell lymphoma, Product Launches, Psoriatic Arthritis, Renal Cell Carcinoma (RCC), Rheumatoid Arthritis, Therapeutics, Top 200 Medicines, Ulcerative Colitis, UveitisHumira’s dominance continues as the world’s top-selling prescription product as the biologic therapy is the first drug to exceed $20 billion in annual global sales.
Vical Incorporated and Brickell Biotech Inc. announced a definitive merger agreement under which Brickell would merge with a wholly owned subsidiary of Vical in an all-stock transaction.
Gilead Sciences Inc. said Kite Pharma Inc., the cancer-focused cell therapy company acquired in 2017, will become a separate business unit.
Imbruvica Plus Gazyva Phase 3 iLLUMINATE Trial for First-Line Therapy of Chronic Lymphocytic Leukemia Patients Met Primary Endpoint
Biopharma, Bruton's Tyrosine Kinase (BTK) Inhibitors, Chronic Lymphocytic Leukemia (CLL), Clinical Studies, Progression-Free Survival (PFS), Small Lymphocytic Lymphoma (SLL)AbbVie, a research-based global biopharmaceutical company, announced that the Phase 3 iLLUMINATE (PCYC-1130) trial met its primary endpoint of improvement in progression-free survival.
The DUO study showed statistically significant PFS improvement for duvelisib versus standard of care treatment ofatumumab.